Surrozen, Inc. SRZN
Surrozen, Inc. (Nasdaq: SRZN) is an ophthalmology drug developer. Its lead program, SZN-8141, is in Pre-clinical for diabetic macular edema; neovascular AMD. Its next catalyst on record is SZN-8141: Initiation of Phase 1b/2a DUET study in DME (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SZN-8141 — Initiation of Phase 1b/2a DUET study in DME (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SZN-8141 | DME, wet AMD | antibody | Pre-clinical |
| SZN-8143 | DME, wet AMD, uveitic macular edema | antibody | Pre-clinical |
| Corneal endothelial and retinal degeneration research programs | corneal endothelial disease; photoreceptor degeneration | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical ophthalmology companies
- Glaukos Corporation GKOS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.